DNA repair mechanisms and their clinical impact in glioblastoma.

Antineoplastic Agents; Biomarkers; Animals; Antineoplastic Agents/pharmacology/therapeutic use; Brain Neoplasms/diagnosis/genetics/metabolism/therapy; DNA Damage/drug effects/radiation effects; DNA Repair/drug effects/radiation effects; Disease Models, Animal; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genetic Therapy; Glioblastoma/diagnosis/genetics/metabolism/therapy; Humans; Radiotherapy; Signal Transduction; Chemoresistance; DNA repair; Glioblastoma; Ionizing radiation; Temozolomide; Therapeutic strategies

Résumé :

[en] Despite surgical resection and genotoxic treatment with ionizing radiation and the DNA alkylating agent temozolomide, glioblastoma remains one of the most lethal cancers, due in great part to the action of DNA repair mechanisms that drive resistance and tumor relapse. Understanding the molecular details of these mechanisms and identifying potential pharmacological targets have emerged as vital tasks to improve treatment. In this review, we introduce the various cellular systems and animal models that are used in studies of DNA repair in glioblastoma. We summarize recent progress in our knowledge of the pathways and factors involved in the removal of DNA lesions induced by ionizing radiation and temozolomide. We introduce the therapeutic strategies relying on DNA repair inhibitors that are currently being tested in vitro or in clinical trials, and present the challenges raised by drug delivery across the blood brain barrier as well as new opportunities in this field. Finally, we review the genetic and epigenetic alterations that help shape the DNA repair makeup of glioblastoma cells, and discuss their potential therapeutic impact and implications for personalized therapy.

Disciplines :

Oncologie

Auteur, co-auteur :

Erasimus, Hélène; NORLUX Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health (LIH), 84 Val Fleuri, L-1526 Luxembourg, Luxembourg.

GOBIN, Matthieu ; NORLUX Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health (LIH), 84 Val Fleuri, L-1526 Luxembourg, Luxembourg.

NICLOU, Simone P. ; NORLUX Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health (LIH), 84 Val Fleuri, L-1526 Luxembourg, Luxembourg.

Van Dyck, Eric; NORLUX Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health (LIH), 84 Val Fleuri, L-1526 Luxembourg, Luxembourg. Electronic address: eric.vandyck@lih.lu.

Co-auteurs externes :

yes

Langue du document :

Anglais

Titre :

DNA repair mechanisms and their clinical impact in glioblastoma.

Date de publication/diffusion :

2024

Titre du périodique :

Mutation Research - Reviews in Mutation Research

ISSN :

1383-5742

eISSN :

1388-2139

Maison d'édition :

Elsevier, Nl

Volume/Tome :

769

Pagination :

19-35

Peer reviewed :

Peer reviewed vérifié par ORBi

Commentaire :

Disponible sur ORBilu :

depuis le 23 février 2024

Statistiques

Nombre de vues

167 (dont 1 Unilu)

Nombre de téléchargements

91 (dont 0 Unilu)

Voir plus de statistiques

citations Scopus^®

145

citations Scopus^®
sans auto-citations

140

OpenCitations

123

citations OpenAlex

175

Bibliographie

Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352:987-996.
Inda M.M., Bonavia R., Mukasa A., Narita Y., Sah D.W., Vandenberg S., Brennan C., Johns T.G., Bachoo R., Hadwiger P., et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev. 2010, 24:1731-1745.
Vartanian A., Singh S.K., Agnihotri S., Jalali S., Burrell K., Aldape K.D., Zadeh G. GBM's multifaceted landscape: highlighting regional and microenvironmental heterogeneity. Neuro Oncol. 2014, 16:1167-1175.
Brennan C.W., Verhaak R.G., McKenna A., Campos B., Noushmehr H., Salama S.R., Zheng S., Chakravarty D., Sanborn J.Z., Berman S.H., et al. The somatic genomic landscape of glioblastoma. Cell 2013, 155:462-477.
Sturm D., Bender S., Jones D.T., Lichter P., Grill J., Becher O., Hawkins C., Majewski J., Jones C., Costello J.F., et al. Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat. Rev. Cancer 2014, 14:92-107.
Sottoriva A., Spiteri I., Piccirillo S.G., Touloumis A., Collins V.P., Marioni J.C., Curtis C., Watts C., Tavare S. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:4009-4014.
Stieber D., Golebiewska A., Evers L., Lenkiewicz E., Brons N.H., Nicot N., Oudin A., Bougnaud S., Hertel F., Bjerkvig R., et al. Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes. Acta Neuropathol. 2014, 127:203-219.
Soeda A., Hara A., Kunisada T., Yoshimura S., Iwama T., Park D.M. The evidence of glioblastoma heterogeneity. Sci. Rep. 2015, 5:7979.
Kim H., Zheng S., Amini S.S., Virk S.M., Mikkelsen T., Brat D.J., Grimsby J., Sougnez C., Muller F., Hu J., et al. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res. 2015, 25:316-327.
Rivera M., Sukhdeo K., Yu J. Ionizing radiation in glioblastoma initiating cells. Front. Oncol. 2013, 3:74.
Nickoloff J.A. DNA repair dysregulation in cancer: from molecular mechanisms to synthetic lethal opportunities. Stress Response PAthways in Cancer - Book 2015, 7-28.
Dietlein F., Thelen L., Reinhardt H.C. Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. Trends Genet. 2014, 30:326-339.
Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
Begg A.C., Stewart F.A., Vens C. Strategies to improve radiotherapy with targeted drugs. Nat. Rev. Cancer 2011, 11:239-253.
Ciccia A., Elledge S.J. The DNA damage response: making it safe to play with knives. Mol. Cell 2010, 40:179-204.
Fu D., Calvo J.A., Samson L.D. Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat. Rev. Cancer 2012, 12:104-120.
Wyatt M.D., Pittman D.L. Methylating agents and DNA repair responses: methylated bases and sources of strand breaks. Chem. Res. Toxicol. 2006, 19:1580-1594.
Duncan T., Trewick S.C., Koivisto P., Bates P.A., Lindahl T., Sedgwick B. Reversal of DNA alkylation damage by two human dioxygenases. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:16660-16665.
Wang P., Wu J., Ma S., Zhang L., Yao J., Hoadley K.A., Wilkerson M.D., Perou C.M., Guan K.L., Ye D., et al. Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents. Cell Rep. 2015, 13:2353-2361.
Johannessen T.C., Prestegarden L., Grudic A., Hegi M.E., Tysnes B.B., Bjerkvig R. The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells. Neuro Oncol. 2013, 15:269-278.
Jacobs A.L., Schar P. DNA glycosylases: in DNA repair and beyond. Chromosoma 2012, 121:1-20.
Dueva R.I.R. Alternative pathways of non-homologous end joining (NHEJ) in genomic instability and cancer. Transl. Cancer Res. 2013, 2(3):163-177.
Kim H., D'Andrea A.D. Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway. Genes Dev. 2012, 26:1393-1408.
Della-Maria J., Zhou Y., Tsai M.S., Kuhnlein J., Carney J.P., Paull T.T., Tomkinson A.E. Human Mre11/human Rad50/Nbs1 and DNA ligase IIIalpha/XRCC1 protein complexes act together in an alternative nonhomologous end joining pathway. J. Biol. Chem. 2011, 286:33845-33853.
Truong L.N., Li Y., Shi L.Z., Hwang P.Y., He J., Wang H., Razavian N., Berns M.W., Wu X. Microhomology-mediated end joining and homologous recombination share the initial end resection step to repair DNA double-strand breaks in mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:7720-7725.
Haracska L., Prakash S., Prakash L. Replication past O(6)-methylguanine by yeast and human DNA polymerase eta. Mol. Cell. Biol. 2000, 20:8001-8007.
Roos W.P., Tsaalbi-Shtylik A., Tsaryk R., Guvercin F., de Wind N., Kaina B. The translesion polymerase Rev3L in the tolerance of alkylating anticancer drugs. Mol. Pharmacol. 2009, 76:927-934.
Yamanaka K., Dorjsuren D., Eoff R.L., Egli M., Maloney D.J., Jadhav A., Simeonov A., Lloyd R.S. A comprehensive strategy to discover inhibitors of the translesion synthesis DNA polymerase kappa. PLoS One 2012, 7:e45032.
Esteller M., Hamilton S.R., Burger P.C., Baylin S.B., Herman J.G. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999, 59:793-797.
Esteller M., Toyota M., Sanchez-Cespedes M., Capella G., Peinado M.A., Watkins D.N., Issa J.P., Sidransky D., Baylin S.B., Herman J.G. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res. 2000, 60:2368-2371.
Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., Kros J.M., Hainfellner J.A., Mason W., Mariani L., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005, 352:997-1003.
Hunter C., Smith R., Cahill D.P., Stephens P., Stevens C., Teague J., Greenman C., Edkins S., Bignell G., Davies H., et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res. 2006, 66:3987-3991.
Chen C.C., Taniguchi T., D'Andrea A. The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents. J. Mol. Med. (Berl.) 2007, 85:497-509.
Kondo N., Takahashi A., Mori E., Noda T., Zdzienicka M.Z., Thompson L.H., Helleday T., Suzuki M., Kinashi Y., Masunaga S., et al. FANCD1/BRCA2 plays predominant role in the repair of DNA damage induced by ACNU or TMZ. PLoS One 2011, 6:e19659.
Bartek J., Ng K., Bartek J., Fischer W., Carter B., Chen C.C. Key concepts in glioblastoma therapy. J. Neurol. Neurosurg. Psychiatry 2012, 83:753-760.
Wick W., Weller M., van den Bent M., Sanson M., Weiler M., von Deimling A., Plass C., Hegi M., Platten M., Reifenberger G. MGMT testing-the challenges for biomarker-based glioma treatment. Nat. Rev. Neurol. 2014, 10:372-385.
Yoshimoto K., Mizoguchi M., Hata N., Murata H., Hatae R., Amano T., Nakamizo A., Sasaki T. Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma. Front. Oncol. 2012, 2:186.
Deans A.J., West S.C. DNA interstrand crosslink repair and cancer. Nat. Rev. Cancer 2011, 11:467-480.
Marteijn J.A., Lans H., Vermeulen W., Hoeijmakers J.H. Understanding nucleotide excision repair and its roles in cancer and ageing. Nat. Rev. Mol. Cell Biol. 2014, 15:465-481.
Vredenburgh J.J., Desjardins A., Reardon D.A., Friedman H.S. Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol. 2009, 11:80-91.
Molina E.S., Pillat M.M., Moura-Neto V., Lah T.T., Ulrich H. Glioblastoma stem-like cells: approaches for isolation and characterization. J. Cancer Stem Cell Res. 2014, 1:1.
Beier D., Schulz J.B., Beier C.P. Chemoresistance of glioblastoma cancer stem cells?much more complex than expected. Mol. Cancer 2011, 10:128.
Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
Chen J., Li Y., Yu T.S., McKay R.M., Burns D.K., Kernie S.G., Parada L.F. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012, 488:522-526.
Tamura K., Aoyagi M., Wakimoto H., Ando N., Nariai T., Yamamoto M., Ohno K. Accumulation of CD133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation. J. Neurosurg. 2010, 113:310-318.
Pollard S.M., Yoshikawa K., Clarke I.D., Danovi D., Stricker S., Russell R., Bayani J., Head R., Lee M., Bernstein M., et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 2009, 4:568-580.
Huszthy P.C., Daphu I., Niclou S.P., Stieber D., Nigro J.M., Sakariassen P.O., Miletic H., Thorsen F., Bjerkvig R. In vivo models of primary brain tumors: pitfalls and perspectives. Neuro Oncol. 2012, 14:979-993.
Ishikawa T., Zhang S.S., Qin X., Takahashi Y., Oda H., Nakatsuru Y., Ide F. DNA repair and cancer: lessons from mutant mouse models. Cancer Sci. 2004, 95:112-117.
Frappart P.O., McKinnon P.J. Mouse models of DNA double-strand break repair and neurological disease. DNA Repair (Amst.) 2008, 7:1051-1060.
Huse J.T., Holland E.C. Genetically engineered mouse models of brain cancer and the promise of preclinical testing. Brain Pathol. 2009, 19:132-143.
Frappart P.O., Lee Y., Russell H.R., Chalhoub N., Wang Y.D., Orii K.E., Zhao J., Kondo N., Baker S.J., McKinnon P.J. Recurrent genomic alterations characterize medulloblastoma arising from DNA double-strand break repair deficiency. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:1880-1885.
Venere M., Hamerlik P., Wu Q., Rasmussen R.D., Song L.A., Vasanji A., Tenley N., Flavahan W.A., Hjelmeland A.B., Bartek J., et al. Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells. Cell Death Differ. 2014, 21:258-269.
Sweeney K.J., Jarzabek M.A., Dicker P., O'Brien D.F., Callanan J.J., Byrne A.T., Prehn J.H. Validation of an imageable surgical resection animal model of Glioblastoma (GBM). J. Neurosci. Methods 2014, 233:99-104.
Daniels D.S., Mol C.D., Arvai A.S., Kanugula S., Pegg A.E., Tainer J.A. Active and alkylated human AGT structures: a novel zinc site, inhibitor and extrahelical base binding. EMBO J. 2000, 19:1719-1730.
Daniels D.S., Woo T.T., Luu K.X., Noll D.M., Clarke N.D., Pegg A.E., Tainer J.A. DNA binding and nucleotide flipping by the human DNA repair protein AGT. Nat. Struct. Mol. Biol. 2004, 11:714-720.
Moen E.L., Stark A.L., Zhang W., Dolan M.E., Godley L.A. The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide. Mol. Cancer Ther. 2014, 13:1334-1344.
Pyko I.V., Nakada M., Sabit H., Teng L., Furuyama N., Hayashi Y., Kawakami K., Minamoto T., Fedulau A.S., Hamada J. Glycogen synthase kinase 3beta inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling. Carcinogenesis 2013, 34:2206-2217.
Kohsaka S., Wang L., Yachi K., Mahabir R., Narita T., Itoh T., Tanino M., Kimura T., Nishihara H., Tanaka S. STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression. Mol. Cancer Ther. 2012, 11:1289-1299.
Siebzehnrubl F.A., Silver D.J., Tugertimur B., Deleyrolle L.P., Siebzehnrubl D., Sarkisian M.R., Devers K.G., Yachnis A.T., Kupper M.D., Neal D., et al. The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance. EMBO Mol. Med. 2013, 5:1196-1212.
Okada M., Sato A., Shibuya K., Watanabe E., Seino S., Suzuki S., Seino M., Narita Y., Shibui S., Kayama T., et al. JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression. Int. J. Oncol. 2014, 44:591-599.
Paranjpe A., Zhang R., Ali-Osman F., Bobustuc G.C., Srivenugopal K.S. Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage. Carcinogenesis 2014, 35:692-702.
Terashima I., Kohda K. Inhibition of human O6-alkylguanine-DNA alkyltransferase and potentiation of the cytotoxicity of chloroethylnitrosourea by 4(6)-(benzyloxy)-2,6(4)-diamino-5-(nitro or nitroso)pyrimidine derivatives and analogues. J. Med. Chem. 1998, 41:503-508.
Bocangel D., Sengupta S., Mitra S., Bhakat K.K. p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor. Anticancer Res. 2009, 29:3741-3750.
Kushwaha D. A genome-wide miRNA screen revealed miR-603 as a MGMT-regulating miRNA in glioblastomas. Oncotarget 2014, 5.
Bieging K.T., Mello S.S., Attardi L.D. Unravelling mechanisms of p53-mediated tumour suppression. Nat. Rev. Cancer 2014, 14:359-370.
Verhaak R.G., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., Miller C.R., Ding L., Golub T., Mesirov J.P., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110.
Rao S.K., Edwards J., Joshi A.D., Siu I.M., Riggins G.J. A survey of glioblastoma genomic amplifications and deletions. J. Neurooncol. 2010, 96:169-179.
Yoshino A., Ogino A., Yachi K., Ohta T., Fukushima T., Watanabe T., Katayama Y., Okamoto Y., Naruse N., Sano E. Effect of IFN-beta on human glioma cell lines with temozolomide resistance. Int. J. Oncol. 2009, 35:139-148.
Happold C., Roth P., Silginer M., Florea A.M., Lamszus K., Frei K., Deenen R., Reifenberger G., Weller M. Interferon-beta induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells. Mol. Cancer Ther. 2014, 13:948-961.
Motomura K., Natsume A., Kishida Y., Higashi H., Kondo Y., Nakasu Y., Abe T., Namba H., Wakai K., Wakabayashi T. Benefits of interferon-beta and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: a multicenter study. Cancer 2011, 117:1721-1730.
Kreth S., Limbeck E., Hinske L.C., Schutz S.V., Thon N., Hoefig K., Egensperger R., Kreth F.W. In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing. Acta Neuropathol. 2013, 125:671-681.
Quintavalle C., Mangani D., Roscigno G., Romano G., Diaz-Lagares A., Iaboni M., Donnarumma E., Fiore D., De Marinis P., Soini Y., et al. MiR-221/222 target the DNA methyltransferase MGMT in glioma cells. PLoS One 2013, 8:e74466.
Zhang W., Zhang J., Hoadley K., Kushwaha D., Ramakrishnan V., Li S., Kang C., You Y., Jiang C., Song S.W., et al. miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. Neuro Oncol. 2012, 14:712-719.
Slaby O., Lakomy R., Fadrus P., Hrstka R., Kren L., Lzicarova E., Smrcka M., Svoboda M., Dolezalova H., Novakova J., et al. MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients. Neoplasma 2010, 57:264-269.
Li R., Gao K., Luo H., Wang X., Shi Y., Dong Q., Luan W., You Y. Identification of intrinsic subtype-specific prognostic microRNAs in primary glioblastoma. J. Exp. Clin. Cancer Res. 2014, 33:9.
Quinn J.A., Jiang S.X., Reardon D.A., Desjardins A., Vredenburgh J.J., Rich J.N., Gururangan S., Friedman A.H., Bigner D.D., Sampson J.H., et al. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J. Clin. Oncol. 2009, 27:1262-1267.
Ranson M., Middleton M.R., Bridgewater J., Lee S.M., Dawson M., Jowle D., Halbert G., Waller S., McGrath H., Gumbrell L., et al. Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res. 2006, 12:1577-1584.
Koch D., Hundsberger T., Boor S., Kaina B. Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma. J. Neurooncol. 2007, 82:85-89.
Kaina B., Muhlhausen U., Piee-Staffa A., Christmann M., Garcia Boy R., Rosch F., Schirrmacher R. Inhibition of O6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors: comparison with nonconjugated inhibitors and effect on fotemustine and temozolomide-induced cell death. J. Pharmacol. Exp. Ther. 2004, 311:585-593.
Javanmard S., Loktionova N.A., Fang Q., Pauly G.T., Pegg A.E., Moschel R.C. Inactivation of O(6)-alkylguanine-DNA alkyltransferase by folate esters of O(6)-benzyl-2'-deoxyguanosine and of O(6)-[4-(hydroxymethyl)benzyl]guanine. J. Med. Chem. 2007, 50:5193-5201.
Beard B.C., Trobridge G.D., Ironside C., McCune J.S., Adair J.E., Kiem H.P. Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. J. Clin. Invest. 2010, 120:2345-2354.
Adair J.E., Beard B.C., Trobridge G.D., Neff T., Rockhill J.K., Silbergeld D.L., Mrugala M.M., Kiem H.P. Extended survival of glioblastoma patients after chemoprotective HSC gene therapy. Sci. Transl. Med. 2012, 4:133ra157.
Adair J.E., Johnston S.K., Mrugala M.M., Beard B.C., Guyman L.A., Baldock A.L., Bridge C.A., Hawkins-Daarud A., Gori J.L., Born D.E., et al. Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients. J. Clin. Invest. 2014, 124:4082-4092.
Liu P., Brown S., Goktug T., Channathodiyil P., Kannappan V., Hugnot J.P., Guichet P.O., Bian X., Armesilla A.L., Darling J.L., et al. Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells. Br. J. Cancer 2012, 107:1488-1497.
Nakada M., Furuta T., Hayashi Y., Minamoto T., Hamada J. The strategy for enhancing temozolomide against malignant glioma. Front. Oncol. 2012, 2:98.
Weber A.M., Ryan A.J. ATM and ATR as therapeutic targets in cancer. Pharmacol. Ther. 2015, 149:124-138.
Squatrito M., Brennan C.W., Helmy K., Huse J.T., Petrini J.H., Holland E.C. Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell 2010, 18:619-629.
Bartkova J., Hamerlik P., Stockhausen M.T., Ehrmann J., Hlobilkova A., Laursen H., Kalita O., Kolar Z., Poulsen H.S., Broholm H., et al. Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas. Oncogene 2010, 29:5095-5102.
Carruthers R., Ahmed S.U., Strathdee K., Gomez-Roman N., Amoah-Buahin E., Watts C., Chalmers A.J. Abrogation of radioresistance in glioblastoma stem-like cells by inhibition of ATM kinase. Mol. Oncol. 2015, 9:192-203.
Golding S.E., Rosenberg E., Valerie N., Hussaini I., Frigerio M., Cockcroft X.F., Chong W.Y., Hummersone M., Rigoreau L., Menear K.A., et al. Improved ATM. kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol. Cancer Ther. 2009, 8:2894-2902.
Biddlestone-Thorpe L., Sajjad M., Rosenberg E., Beckta J.M., Valerie N.C., Tokarz M., Adams B.R., Wagner A.F., Khalil A., Gilfor D., et al. ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation. Clin. Cancer Res. 2013, 19:3189-3200.
Reinhardt H.C., Jiang H., Hemann M.T., Yaffe M.B. Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle 2009, 8:3112-3119.
Durant S., Karlin J., Ahmad S., Beckta J., Tokarz M., Mukhopadhyay N.D., Barlaam B., Wilson J., Patel B., Thomason A., et al. Orally bioavailable BBB-penetrant ATM inhibitor radiosensitises glioma in mice. 14th International Wolfsberg Meeting on Molecular Radiation Biology/Oncology 2015.
Ito M., Ohba S., Gaensler K., Ronen S.M., Mukherjee J., Pieper R.O. Early Chk1 phosphorylation is driven by temozolomide-induced, DNA double strand break- and mismatch repair-independent DNA damage. PLoS One 2013, 8:e62351.
Eich M., Roos W.P., Nikolova T., Kaina B. Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide. Mol. Cancer Ther. 2013, 12:2529-2540.
Flynn R.L., Cox K.E., Jeitany M., Wakimoto H., Bryll A.R., Ganem N.J., Bersani F., Pineda J.R., Suva M.L., Benes C.H., et al. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science 2015, 347:273-277.
Heaphy C.M., Subhawong A.P., Hong S.M., Goggins M.G., Montgomery E.A., Gabrielson E., Netto G.J., Epstein J.I., Lotan T.L., Westra W.H., et al. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am. J. Pathol. 2011, 179:1608-1615.
Agnihotri S., Burrell K., Buczkowicz P., Remke M., Golbourn B., Chornenkyy Y., Gajadhar A., Fernandez N.A., Clarke I.D., Barszczyk M.S., et al. ATM regulates 3-methylpurine-DNA glycosylase and promotes therapeutic resistance to alkylating agents. Cancer Discov. 2014, 4:1198-1213.
Agnihotri S., Gajadhar A.S., Ternamian C., Gorlia T., Diefes K.L., Mischel P.S., Kelly J., McGown G., Thorncroft M., Carlson B.L., et al. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. J. Clin. Invest. 2012, 122:253-266.
Goellner E.M., Grimme B., Brown A.R., Lin Y.C., Wang X.H., Sugrue K.F., Mitchell L., Trivedi R.N., Tang J.B., Sobol R.W. Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair. Cancer Res. 2011, 71:2308-2317.
Quiros S., Roos W.P., Kaina B. Rad51 and BRCA2-new molecular targets for sensitizing glioma cells to alkylating anticancer drugs. PLoS One 2011, 6:e27183.
Squatrito M., Vanoli F., Schultz N., Jasin M., Holland E.C. 53BP1 is a haploinsufficient tumor suppressor and protects cells from radiation response in glioma. Cancer Res. 2012, 72:5250-5260.
Short S.C., Giampieri S., Worku M., Alcaide-German M., Sioftanos G., Bourne S., Lio K.I., Shaked-Rabi M., Martindale C. Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells. Neuro Oncol. 2011, 13:487-499.
Lim Y.C., Roberts T.L., Day B.W., Stringer B.W., Kozlov S., Fazry S., Bruce Z.C., Ensbey K.S., Walker D.G., Boyd A.W., et al. Increased sensitivity to ionizing radiation by targeting the homologous recombination pathway in glioma initiating cells. Mol. Oncol. 2014, 8:1603-1615.
Kondo N., Takahashi A., Mori E., Ohnishi K., McKinnon P.J., Sakaki T., Nakase H., Ohnishi T. DNA ligase IV as a new molecular target for temozolomide. Biochem. Biophys. Res. Commun. 2009, 387:656-660.
Rivera M., Wu Q., Hamerlik P., Hjelmeland A.B., Bao S., Rich J.N. Acquisition of meiotic DNA repair regulators maintain genome stability in glioblastoma. Cell. Death. Dis. 2015, 6:e1732.
Liou G.Y., Storz P. Reactive oxygen species in cancer. Free Radic. Res. 2010, 44:479-496.
Gan H.K., Cvrljevic A.N., Johns T.G. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. FEBS J. 2013, 280:5350-5370.
Nitta M., Kozono D., Kennedy R., Stommel J., Ng K., Zinn P.O., Kushwaha D., Kesari S., Inda M.M., Wykosky J., et al. Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy. PLoS One 2010, 5:e10767.
Luo J., Solimini N.L., Elledge S.J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136:823-837.
Mukherjee B., McEllin B., Camacho C.V., Tomimatsu N., Sirasanagandala S., Nannepaga S., Hatanpaa K.J., Mickey B., Madden C., Maher E., et al. EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res. 2009, 69:4252-4259.
Lopes I.C., Oliveira S.C., Oliveira-Brett A.M. In situ electrochemical evaluation of anticancer drug temozolomide and its metabolites-DNA interaction. Anal. Bioanal. Chem. 2013, 405:3783-3790.
Ozben T. Oxidative stress and apoptosis: impact on cancer therapy. J. Pharm. Sci. 2007, 96:2181-2196.
Svilar D., Dyavaiah M., Brown A.R., Tang J.B., Li J., McDonald P.R., Shun T.Y., Braganza A., Wang X.H., Maniar S., et al. Alkylation sensitivity screens reveal a conserved cross-species functionome. Mol. Cancer Res. 2012, 10:1580-1596.
Rouleau M., Patel A., Hendzel M.J., Kaufmann S.H., Poirier G.G. PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer 2010, 10:293-301.
Michels J., Vitale I., Saparbaev M., Castedo M., Kroemer G. Predictive biomarkers for cancer therapy with PARP inhibitors. Oncogene 2014, 33:3894-3907.
Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol. Oncol. 2011, 5:387-393.
Lord C.J., McDonald S., Swift S., Turner N.C., Ashworth A. A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Repair (Amst.) 2008, 7:2010-2019.
Strom C.E., Johansson F., Uhlen M., Szigyarto C.A., Erixon K., Helleday T. Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. Nucleic Acids Res. 2011, 39:3166-3175.
Horton J.K., Stefanick D.F., Prasad R., Gassman N.R., Kedar P.S., Wilson S.H. Base excision repair defects invoke hypersensitivity to PARP inhibition. Mol. Cancer Res. 2014, 12:1128-1139.
Dungey F.A., Loser D.A., Chalmers A.J. Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int. J. Radiat. Oncol. Biol. Phys. 2008, 72:1188-1197.
Russo A.L., Kwon H.C., Burgan W.E., Carter D., Beam K., Weizheng X., Zhang J., Slusher B.S., Chakravarti A., Tofilon P.J., et al. In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clin. Cancer Res. 2009, 15:607-612.
Barazzuol L., Jena R., Burnet N.G., Meira L.B., Jeynes J.C., Kirkby K.J., Kirkby N.F. Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma. Radiat. Oncol. 2013, 8:65.
Fojo T., Bates S. Mechanisms of resistance to PARP inhibitors-three and counting. Cancer Discov. 2013, 3:20-23.
Majuelos-Melguizo PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma. Oncotarget 2014, 6(7):4790-4803.
Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068.
Ohba S., Mukherjee J., See W.L., Pieper R.O. Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance. Cancer Res. 2014, 74:4836-4844.
Rohle D., Popovici-Muller J., Palaskas N., Turcan S., Grommes C., Campos C., Tsoi J., Clark O., Oldrini B., Komisopoulou E., et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013, 340:626-630.
Phillips J.J., Aranda D., Ellison D.W., Judkins A.R., Croul S.E., Brat D.J., Ligon K.L., Horbinski C., Venneti S., Zadeh G., et al. PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. Brain Pathol. 2013, 23:565-573.
Kao G.D., Jiang Z., Fernandes A.M., Gupta A.K., Maity A. Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation. J. Biol. Chem. 2007, 282:21206-21212.
McEllin B., Camacho C.V., Mukherjee B., Hahm B., Tomimatsu N., Bachoo R.M., Burma S. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res. 2010, 70:5457-5464.
Xu J., Li Z., Wang J., Chen H., Fang J.Y. Combined PTEN mutation and protein expression associate with overall and disease-Free survival of glioblastoma patients. Transl. Oncol. 2014, 7:196-205. e191.
Wang X., Chen J.X., Liu Y.H., You C., Mao Q. Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase. Neurol. Sci. 2013, 34:1421-1428.
Behjati S., Tarpey P.S., Presneau N., Scheipl S., Pillay N., Van Loo P., Wedge D.C., Cooke S.L., Gundem G., Davies H., et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat. Genet. 2013, 45:1479-1482.
Khuong-Quang D.A., Buczkowicz P., Rakopoulos P., Liu X.Y., Fontebasso A.M., Bouffet E., Bartels U., Albrecht S., Schwartzentruber J., Letourneau L., et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol. 2012, 124:439-447.
Schwartzentruber J., Korshunov A., Liu X.Y., Jones D.T., Pfaff E., Jacob K., Sturm D., Fontebasso A.M., Quang D.A., Tonjes M., et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012, 482:226-231.
Wu G., Broniscer A., McEachron T.A., Lu C., Paugh B.S., Becksfort J., Qu C., Ding L., Huether R., Parker M., et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat. Genet. 2012, 44:251-253.
Conte D., Huh M., Goodall E., Delorme M., Parks R.J., Picketts D.J. Loss of Atrx sensitizes cells to DNA damaging agents through p53-mediated death pathways. PLoS One 2012, 7:e52167.
Carvalho S., Vitor A.C., Sridhara S.C., Martins F.B., Raposo A.C., Desterro J.M., Ferreira J., de Almeida S.F. SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint. Elife 2014, 3:e02482.
Fontebasso A.M., Schwartzentruber J., Khuong-Quang D.A., Liu X.Y., Sturm D., Korshunov A., Jones D.T., Witt H., Kool M., Albrecht S., et al. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathol. 2013, 125:659-669.
Li F., Mao G., Tong D., Huang J., Gu L., Yang W., Li G.M. The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSalpha. Cell 2013, 153:590-600.
Pfister S.X., Ahrabi S., Zalmas L.P., Sarkar S., Aymard F., Bachrati C.Z., Helleday T., Legube G., La Thangue N.B., Porter A.C., et al. SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability. Cell Rep. 2014, 7:2006-2018.
de Vries N.A., Hulsman D., Akhtar W., de Jong J., Miles D.C., Blom M., van Tellingen O., Jonkers J., van Lohuizen M. Prolonged ezh2 depletion in glioblastoma causes a robust switch in cell fate resulting in tumor progression. Cell Rep. 2015, 10:383-397.
Orzan F., Pellegatta S., Poliani P.L., Pisati F., Caldera V., Menghi F., Kapetis D., Marras C., Schiffer D., Finocchiaro G. Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells. Neuropathol. Appl. Neurobiol. 2011, 37:381-394.
Zhang J., Chen L., Han L., Shi Z., Zhang J., Pu P., Kang C. EZH2 is a negative prognostic factor and exhibits pro-oncogenic activity in glioblastoma. Cancer Lett. 2015, 356:929-936.
Boldrini L., Pistolesi S., Gisfredi S., Ursino S., Ali G., Pieracci N., Basolo F., Parenti G., Fontanini G. Telomerase activity and hTERT mRNA expression in glial tumors. Int. J. Oncol. 2006, 28:1555-1560.
Lotsch D., Ghanim B., Laaber M., Wurm G., Weis S., Lenz S., Webersinke G., Pichler J., Berger W., Spiegl-Kreinecker S. Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age. Neuro Oncol. 2013, 15:423-432.
Shin K.H., Kang M.K., Dicterow E., Kameta A., Baluda M.A., Park N.H. Introduction of human telomerase reverse transcriptase to normal human fibroblasts enhances DNA repair capacity. Clin. Cancer Res. 2004, 10:2551-2560.
Simon M., Hosen I., Gousias K., Rachakonda S., Heidenreich B., Gessi M., Schramm J., Hemminki K., Waha A., Kumar R. TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro Oncol. 2015, 17:45-52.
Guo P., Lan J., Ge J., Mao Q., Qiu Y. ID1 regulates U87 human cell proliferation and invasion. Oncol. Lett. 2013, 6:921-926.
Guo Q., Guo P., Mao Q., Lan J., Lin Y., Jiang J., Qiu Y. ID1 affects the efficacy of radiotherapy in glioblastoma through inhibition of DNA repair pathways. Med. Oncol. 2013, 30:325.
Bandey I., Chiou S.H., Huang A.P., Tsai J.C., Tu P.H. Progranulin promotes Temozolomide resistance of glioblastoma by orchestrating DNA repair and tumor stemness. Oncogene 2015, 34:1853-1864.
Fischer U., Hemmer D., Heckel D., Michel A., Feiden W., Steudel W.I., Hulsebos T., Meese E. KUB3 amplification and overexpression in human gliomas. Glia 2001, 36:1-10.
Fischer U., Rheinheimer S., Krempler A., Lobrich M., Meese E. Glioma-amplified sequence KUB3 influences double-strand break repair after ionizing radiation. Int. J. Oncol. 2013, 43:50-56.
Foote M.B., Papadopoulos N., Diaz L.A. Genetic classification of gliomas: refining histopathology. Cancer Cell 2015, 28:9-11.
Eckel-Passow J.E., Lachance D.H., Molinaro A.M., Walsh K.M., Decker P.A., Sicotte H., Pekmezci M., Rice T., Kosel M.L., Smirnov I.V., et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N. Engl. J. Med. 2015, 372:2499-2508.
Doksani Y., de Lange T. The role of double-strand break repair pathways at functional and dysfunctional telomeres. Cold Spring Harb. Perspect Biol. 2014, 6:a016576.
Killela P.J., Reitman Z.J., Jiao Y., Bettegowda C., Agrawal N., Diaz L.A., Friedman A.H., Friedman H., Gallia G.L., Giovanella B.C., et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:6021-6026.
Spiegl-Kreinecker S., Lotsch D., Ghanim B., Pirker C., Mohr T., Laaber M., Weis S., Olschowski A., Webersinke G., Pichler J., et al. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis. Neuro Oncol. 2015, 17:1231-1240.
Masutomi K., Possemato R., Wong J.M., Currier J.L., Tothova Z., Manola J.B., Ganesan S., Lansdorp P.M., Collins K., Hahn W.C. The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:8222-8227.
Marian C.O., Cho S.K., McEllin B.M., Maher E.A., Hatanpaa K.J., Madden C.J., Mickey B.E., Wright W.E., Shay J.W., Bachoo R.M. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin. Cancer Res. 2010, 16:154-163.
Merle P., Evrard B., Petitjean A., Lehn J.M., Teulade-Fichou M.P., Chautard E., De Cian A., Guittat L., Tran P.L., Mergny J.L., et al. Telomere targeting with a new G4 ligand enhances radiation-induced killing of human glioblastoma cells. Mol. Cancer Ther. 2011, 10:1784-1795.
Jeitany M., Pineda J.R., Liu Q., Porreca R.M., Hoffschir F., Desmaze C., Silvestre D.C., Mailliet P., Junier M.P., Londono-Vallejo A., et al. A preclinical mouse model of glioma with an alternative mechanism of telomere maintenance (ALT). Int. J. Cancer 2015, 136:1546-1558.
Silvestre D.C., Pineda J.R., Hoffschir F., Studler J.M., Mouthon M.A., Pflumio F., Junier M.P., Chneiweiss H., Boussin F.D. Alternative lengthening of telomeres in human glioma stem cells. Stem Cells 2011, 29:440-451.
Fangusaro J. Pediatric high grade glioma: a review and update on tumor clinical characteristics and biology. Front. Oncol. 2012, 2:105.
Yuen B.T., Knoepfler P.S. Histone H3.3 mutations: a variant path to cancer. Cancer Cell 2013, 24:567-574.
Sturm D., Witt H., Hovestadt V., Khuong-Quang D.A., Jones D.T., Konermann C., Pfaff E., Tonjes M., Sill M., Bender S., et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012, 22:425-437.
Lewis P.W., Elsaesser S.J., Noh K.M., Stadler S.C., Allis C.D. Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:14075-14080.
Wong L.H., McGhie J.D., Sim M., Anderson M.A., Ahn S., Hannan R.D., George A.J., Morgan K.A., Mann J.R., Choo K.H. ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells. Genome Res. 2010, 20:351-360.
Lewis P.W., Muller M.M., Koletsky M.S., Cordero F., Lin S., Banaszynski L.A., Garcia B.A., Muir T.W., Becher O.J., Allis C.D. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 2013, 340:857-861.
Gallo M., Coutinho F.J., Vanner R.J., Gayden T., Mack S.C., Murison A., Remke M., Li R., Takayama N., Desai K., et al. MLL5 orchestrates a cancer self-renewal state by repressing the histone variant H3.3 and globally reorganizing chromatin. Cancer Cell 2015, 28:715-729.
Crea F., Hurt E.M., Farrar W.L. Clinical significance of polycomb gene expression in brain tumors. Mol. Cancer 2010, 9:265.
Aymard F., Bugler B., Schmidt C.K., Guillou E., Caron P., Briois S., Iacovoni J.S., Daburon V., Miller K.M., Jackson S.P., et al. Transcriptionally active chromatin recruits homologous recombination at DNA double-strand breaks. Nat. Struct. Mol. Biol. 2014, 21:366-374.
Roy D.M., Walsh L.A., Chan T.A. Driver mutations of cancer epigenomes. Protein Cell 2014, 5:265-296.
Cohen A.L., Holmen S.L., Colman H. IDH1 and IDH2 mutations in gliomas. Curr. Neurol. Neurosci. Rep. 2013, 13:345.
Ichimura K., Pearson D.M., Kocialkowski S., Backlund L.M., Chan R., Jones D.T., Collins V.P. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol. 2009, 11:341-347.
Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., Kos I., Batinic-Haberle I., Jones S., Riggins G.J., et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 2009, 360:765-773.
Chowdhury R., Yeoh K.K., Tian Y.M., Hillringhaus L., Bagg E.A., Rose N.R., Leung I.K., Li X.S., Woon E.C., Yang M., et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 2011, 12:463-469.
Figueroa M.E., Abdel-Wahab O., Lu C., Ward P.S., Patel J., Shih A., Li Y., Bhagwat N., Vasanthakumar A., Fernandez H.F., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18:553-567.
Losman J.A., Kaelin W.G. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 2013, 27:836-852.
Noushmehr H., Weisenberger D.J., Diefes K., Phillips H.S., Pujara K., Berman B.P., Pan F., Pelloski C.E., Sulman E.P., Bhat K.P., et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010, 17:510-522.
Turcan S., Rohle D., Goenka A., Walsh L.A., Fang F., Yilmaz E., Campos C., Fabius A.W., Lu C., Ward P.S., et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012, 483:479-483.
Ceccarelli M., Barthel F.P., Malta T.M., Sabedot T.S., Salama S.R., Murray B.A., Morozova O., Newton Y., Radenbaugh A., Pagnotta S.M., et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 2016, 164:550-563.
Bleeker F.E., Atai N.A., Lamba S., Jonker A., Rijkeboer D., Bosch K.S., Tigchelaar W., Troost D., Vandertop W.P., Bardelli A., et al. The prognostic IDH1(R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol. 2010, 119:487-494.
Shi J., Zuo H., Ni L., Xia L., Zhao L., Gong M., Nie D., Gong P., Cui D., Shi W., et al. An IDH1 mutation inhibits growth of glioma cells via GSH depletion and ROS generation. Neurol. Sci. 2014, 35:839-845.
Shi J., Sun B., Shi W., Zuo H., Cui D., Ni L., Chen J. Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation. Tumour Biol. 2015, 36:655-662.
Maleszewska M., Kaminska B. Is glioblastoma an epigenetic malignancy?. Cancers (Basel) 2013, 5:1120-1139.
Robert C., Rassool F.V. HDAC inhibitors: roles of DNA damage and repair. Adv. Cancer Res. 2012, 116:87-129.
Smith S., Fox J., Mejia M., Ruangpradit W., Saberi A., Kim S., Choi Y., Oh S., Wang Y., Choi K., et al. Histone deacetylase inhibitors selectively target homology dependent DNA repair defective cells and elevate non-homologous endjoining activity. PLoS One 2014, 9:e87203.
Jin B., Robertson K.D. DNA methyltransferases, DNA damage repair, and cancer. Adv. Exp. Med. Biol. 2013, 754:3-29.
Kim H.J., Kim J.H., Chie E.K., Young P.D., Kim I.A., Kim I.H. DNMT (DNA methyltransferase) inhibitors radiosensitize human cancer cells by suppressing DNA repair activity. Radiat. Oncol. 2012, 7:39.
Jacobs V.L., Valdes P.A., Hickey W.F., De Leo J.A. Current review of in vivo GBM rodent models: emphasis on the CNS-1 tumour model. ASN Neuro 2011, 3:e00063.
De Witt Hamer P.C., Van Tilborg A.A., Eijk P.P., Sminia P., Troost D., Van Noorden C.J., Ylstra B., Leenstra S. The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. Oncogene 2008, 27:2091-2096.
Bougnaud S., Golebiewska A., Oudin A., Keunen O., Harter P.N., Mäder L., Azuaje F., Fritah S., Stieber D., Kaoma T., et al. Molecular crosstalk between tumour and brain parenchyma instructs histopathological features in glioblastoma. Oncotarget 2016, 7(22):31955-31971.
Bottai G., Pasculli B., Calin G.A., Santarpia L. Targeting the microRNA-regulating DNA damage/repair pathways in cancer. Expert Opin. Biol. Ther. 2014, 14:1667-1683.
Park J.Y., Lee J.E., Park J.B., Yoo H., Lee S.H., Kim J.H. Roles of long non-coding RNAs on tumorigenesis and glioma development. Brain Tumor Res. Treat. 2014, 2:1-6.
Laquintana V., Trapani A., Denora N., Wang F., Gallo J.M., Trapani G. New strategies to deliver anticancer drugs to brain tumors. Expert Opin. Drug Deliv. 2009, 6:1017-1032.
Perry J., Chambers A., Spithoff K., Laperriere N. Gliadel wafers in the treatment of malignant glioma: a systematic review. Curr. Oncol. 2007, 14:189-194.
Juratli T.A., Schackert G., Krex D. Current status of local therapy in malignant gliomas - a clinical review of three selected approaches. Pharmacol. Ther. 2013, 139:341-358.
Tsujiuchi T., Natsume A., Motomura K., Kondo G., Ranjit M., Hachisu R., Sugimura I., Tomita S., Takehara I., Woolley M., et al. Preclinical evaluation of an O(6)-methylguanine-DNA methyltransferase-siRNA/liposome complex administered by convection-enhanced delivery to rat and porcine brains. Am. J. Transl. Res. 2014, 6:169-178.
Stephen Z.R., Kievit F.M., Veiseh O., Chiarelli P.A., Fang C., Wang K., Hatzinger S.J., Ellenbogen R.G., Silber J.R., Zhang M. Redox-responsive magnetic nanoparticle for targeted convection-enhanced delivery of O6-benzylguanine to brain tumors. ACS Nano 2014, 8:10383-10395.